DNA2.0 is the bioengineering solutions provider. Founded in 2003, DNA2.0 offers an integrated pipeline of solutions for the research community, including gene design, optimization, synthesis and cloning, as well as platforms for protein and strain engineering. It is the fastest provider of synthetic genes—based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 is by far the most published synthetic gene vendor, providing expert support to and collaboration with scientists. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene design and synthesis processes and new protein optimization technologies. DNA2.0’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. The company is privately held and is headquartered in Menlo Park, California.

Lexicon Pharmaceuticals, Inc. (formerly Lexicon Genetic) a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; collaboration agreement with Taconic Farms, Inc.; and an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.

Fabric Genomics is making genomics-driven precision medicine a reality. We provide clinical decision support software that enables clinical labs, hospital systems and country-sequencing programs to gain actionable genomic insights, resulting in faster and more accurate diagnoses and reduced turnaround time. Fabric’s end-to-end genomic analysis platform incorporates proven AI algorithms, and has applications in both hereditary disease and oncology. Headquartered in Oakland, California, Fabric Genomics was founded by industry veterans and innovators with a deep understanding of bioinformatics, large-scale genomics and clinical diagnostics.

Signal Pharmaceuticals Inc is pioneering the discovery and development of small molecule therapeutics which regulate the transcription factors involved in the progression of a number of inflammatory, viral and neurological diseases. The core technology for the company's research was discovered in the laboratories of three of its founders, and has been licensed from the University of California and the Salk Institute. (SB) It was located in San Diego, CA.

Biocept, an emerging biotechnology leader in cell separation technology, is developing a new, powerful class of diagnostic assays for personalized medicine in early detection, diagnosis and monitoring of cancer. The CEEâ„¢ Cell Enrichment and Extraction platform combines sophisticated attachment chemistry with mathematically modeled fluid dynamics to enable earlier, accurate, less invasive diagnoses. Isolation, purification and analysis of rare cells are managed within their state-of-the-art CLIA-accredited laboratory. The clinical laboratory is accredited by the College of American Pathologists (CAP) and holds licenses in California and several other states.

Immunex Corporation develops, manufactures, and markets therapeutic products for the treatment of cancer, infectious diseases, and autoimmune disorders. It offers products, such as Enbrel that is used in the treatment of rheumatoid arthritis; Novantrone, which is used to treat acute nonlymphocytic leukemia and pain associated with prostate cancer; and Leukine for use in bone marrow transplant patients. The company has franchise operations. It has a strategic alliance with American Home Products. The company was founded in 1981 and is based in Seattle, Washington. As of July 15, 2002, Immunex Corporation was acquired by Amgen, Inc.

Rosetta Inpharmatics LLC designed and implemented DNA microarray gene expression systems. The company provided software for use in informational genomics. The company was founded in may 29, 2009 and was headquartered in Seattle, WA.

The King Faisal Specialist Hospital and Research Centre (Arabic: مستشفى الملك فيصل التخصصي ومركز الأبحاث‎) (KFSH&RC) is tertiary referral hospital in Riyadh, the capital city of Saudi Arabia. As a tertiary referral hospital, it offers primary and highly specialized inpatient and outpatient medical care and participates in many clinical and research studies. It is consistently recognized as one of the nation's top hospital specializing in Oncology, Organ Transplantation, Cardiovascular Diseases, Neurosciences and Genetic Diseases. A large portion of the patient population are referrals from other hospitals from across Saudi Arabia as a whole and the surrounding regions. The hospital handles around 10,000 thousand outpatient visits each year and houses over 1,600 beds and has 28 health outreach centers. It has a staff of over 1,000 doctors with over 13,500 total employees of 67 different nationalities.

Display Systems Biotech As, part of NTG Nordic Transport Group A/S, is a Danish company located in Copenhagen involved in pharmaceutical preparations. The firm was founded by Thomas Warthoe. Display Systems Biotech As was acquired by NTG Nordic Transport Group An on March 21, 2001 for $3.52 million.

Invivoscribe Technologies, Inc. provides hematology-oncology testing products and services. It offers vitro diagnostic cGMP products. The company was founded by Jeffrey Edward Miller and James B. Isaacs, Jr. in 1995 and is headquartered in San Diego, CA.

Agricore United Ltd. supplies crop nutrition and protection products. It offers local and international farmers and end-users with a pipeline of products and services and markets agricultural commodities. The firm also offers integrated grain, oilseeds, livestock and special crops marketing, handling services through a prairie-wide network of elevators & specialized processing plants. The company was founded in November 2001 and is headquartered in Winnipeg, Canada.

Genetwister Technologies BV is a private company headquartered in Wageningen, the Netherlands, that develops biotechnical products for breeding purposes.

Renovis, Inc. is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The Company is currently developing products for acute ischemic stroke, for the treatment of neuropathic pain, and for the treatment of acute post-operative pain.

NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark.

Morphotek is one of the leading companies in the life science industry that develops novel classes of biological-based products to treat cancer, inflammation and infectious diseases. Since its founding in 2000, Morphotek has made extraordinary progress in discovering and developing monoclonal antibodies (mABs) to treat these diseases and continues to develop additional antibody products using its proprietary technologies. Post-graduate research executed by Morphotek’s President and CEO, Dr. Nicholas Nicolaides, during his studies at Johns Hopkins Medical School was the basis for the company’s inception. It was there that Dr. Nicolaides co-invented the company's legacy technology called morphogenics. Along with the honed applications for applying morphogenics for product development refined by the company’s other co-founders, Dr. Philip Sass and Dr. Luigi Grasso, morphogenics has taken Morphotek an incredible distance in the advancement of novel pharmaceutical products and targets.

Signal Pharmaceuticals is a biopharmaceutical company that was founded by David Anderson (Senior VP & Head of Research), Alan Lewis (CEO), Mark Carmen, and Jackie Johnson and is based in California. It was acquired by Celgene in 2009

Weimi Biotechnology (Jiangsu) Co., Ltd., established on 2017-07-24, Business scope includes biotechnology development,technical consulting,Technical Services and Technology Transfer;Genetic testing technology research and development and consulting;laboratory instrument,teaching facility,Chemical raw materials and products(In addition to dangerous goods),Class I medical device,electronic product,computer software development,Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) General project:business training(Does not include education and training,Vocational skills training and other licensed training);Conference and Exhibition Services;Technology promotion and application services;Science popularization service(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

New England Biolabs is focused on the discovery and development of recombinant and native enzymes for genomic research. It offers restriction endonucleases for DNA digestion; PCR, polymerases, and amplification technologies for PCR applications; DNA modifying enzymes and cloning technologies; reagents for DNA and RNA sample preparation; DNA, RNA, and protein markers and ladders for electrophoresis applications; reagents for RNA research; and gene expression tools for DNA, RNA, and protein transfection of cell lines. The company also offers cellular analysis solutions; reagents, enzymes, antibodies, and DNA controls for epigenetics research; protein expression and purification technologies; competent cells for transformation and protein expression; protein tools; glycobiology products; and plasmids and DNAs for use in cloning experiments. New England Biolabs was founded in 1974 and is based in Ipswich, Massachusetts.